The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective manipulation of the gut microbiome with Microbial Ecosystem Therapeutic 4 (MET4) in locoregionally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation (ROMA2).
 
Geoffrey Alan Watson
Honoraria - Pfizer
Travel, Accommodations, Expenses - Abbvie
 
Alya Heirali
No Relationships to Disclose
 
Marc Oliva Bernal
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Mirati Therapeutics
Travel, Accommodations, Expenses - MSD Oncology
Other Relationship - Bristol-Myers Squibb; Merck
 
Kyla Cochrane
No Relationships to Disclose
 
Emma Allen-Vercoe
No Relationships to Disclose
 
Anneli Eliason
No Relationships to Disclose
 
Sarah Jennings
No Relationships to Disclose
 
Rachel Taylor
No Relationships to Disclose
 
Ali Hosni
No Relationships to Disclose
 
Andrew Hope
No Relationships to Disclose
 
Scott Victor Bratman
Stock and Other Ownership Interests - DNAMx
Consulting or Advisory Role - Bristol-Myers Squibb; DNAMx
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Co-inventor and holder of a patent related to circulating tumor DNA detection technology.; Co-inventor of patents related to cell-free DNA methylation analysis technology. (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Douglas Brian Chepeha
No Relationships to Disclose
 
Ilan Weinreb
No Relationships to Disclose
 
Bayardo Perez-Ordonez
No Relationships to Disclose
 
John Waldron
No Relationships to Disclose
 
Wei Xu
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Bryan Coburn
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche